Source: Clive Maund 04/29/2022
After recovering from a short “character assassination,” Reliq Health Technologies may be on the up-and-up. Clive Maund examines the latest data from the company to see if it would make a good ‘buy’.
There is a rather odd divergence between the fortunes of the company Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN), which is gaining more and more contracts and coming out with a stream of positive news and the recent poor performance of its stock price and clearly, if the former is true, it is presenting investors with an opportunity to buy the stock before this divergence corrects itself with an appreciation of the stock.
A reason that the stock declined this month into the 2nd low of the Double Bottom that we can see clearly on its latest 1-year chart is that it has been the victim of a short attack, apparently involving a sort of “character assassination” of the company by means of making allegations which have since been vigorously and decisively refuted and discredited by the company. But whatever the reason the stock looks technically like a buy here with it believed to be at the 2nd low of this Double Bottom which is forming some way beneath a still rising 200-day moving average, with its accumulation line having held up well on the decline from its early February high. However, the case for it turning higher from here looks a lot more convincing on its 5-year chart.
The conclusion is that Reliq Health is a strong buy here for all timeframes. It was included as a buy in a Market Notebook update posted before today’s open.
Reliq Health Technologies website
Get Our Free Metatrader 4 Indicators – Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
Get our Weekly Commitment of Traders Reports - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Reliq Health Technologies RHT.TSX, RQHTF on OTC, trading at C$0.73, $0.572 at 12.15 pm EDT on 26th April 22.
Originally posted on CliveMaund.com on April 26, 2022.
Clive Maund has been president of www.clivemaund.com, a successful resource sector website, since its inception in 2003. He has 30 years’ experience in technical analysis and has worked for banks, commodity brokers, and stockbrokers in the City of London. He holds a Diploma in Technical Analysis from the UK Society of Technical Analysts.
The above represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund’s opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund’s opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.
1) Clive Maund: I, or members of my immediate household or family, own securities of the following companies mentioned in this article: None. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Reliq Health Technologies Inc. Click here for important disclosures about sponsor fees.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Reliq Health Technologies Inc., a company mentioned in this article.